Engrail Therapeutics Acquires NeuroCycle Therapeutics

Cycle Pharmaceuticals (Cycle Group) Acquires Applied Therapeutics, Inc.

February 3, 2026

Pharmaceuticals

Cycle Group Holdings Limited (Cycle Pharmaceuticals) has completed the acquisition of NASDAQ-listed Applied Therapeutics, a clinical-stage biopharmaceutical company focused on novel CNS-penetrant therapies for rare metabolic diseases. The transaction was funded from Cycle's cash on hand and brings Applied's lead candidate govorestat and rare-disease pipeline into Cycle's rare metabolic disease platform.

Biogen Acquires Alcyone Therapeutics

September 19, 2025

Medical Devices

Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.

UCB Acquires Engage Therapeutics

June 5, 2020

Pharmaceuticals

Belgium-based biopharma UCB has acquired Summit, New Jersey-based Engage Therapeutics for an upfront cash payment of US$125 million plus up to US$145 million in milestone payments, gaining worldwide rights to Staccato Alprazolam. The acquisition adds a late-stage, drug-device rescue therapy candidate for epilepsy to UCB's neurology portfolio and includes updated license and supply agreements with Alexza Pharmaceuticals.

Axsome Therapeutics Acquires Baergic Bio to Secure Global Rights to AZD7325

November 8, 2025

Pharmaceuticals

Axsome Therapeutics acquired a 100% equity interest in Baergic Bio (a subsidiary of Avenue Therapeutics) and amended Baergic Bio's license with AstraZeneca to obtain exclusive global rights to AZD7325, an early‑stage selective GABAA α2,3 receptor modulator for epilepsy. The deal includes a $0.3 million upfront payment to Baergic Bio shareholders and potential development, regulatory, sales‑based milestones and tiered royalties to Avenue Therapeutics and AstraZeneca as described in the purchase and amended license agreements.

Johnson & Johnson Acquires Intra-Cellular Therapies

April 2, 2025

Pharmaceuticals

Johnson & Johnson has completed its acquisition of Intra-Cellular Therapies, adding the approved drug CAPLYTA (lumateperone) and a clinical-stage neuroscience pipeline to J&J's Innovative Medicine business. The deal is expected to accelerate J&J's 2025 sales growth and strengthen its leadership in neuroscience and mental health therapeutics.

Bruker Corporation Acquires Neurescence Inc.

November 12, 2022

Medical Devices

Bruker Corporation has signed a definitive agreement to acquire 100% of Neurescence Inc., a Toronto-based developer of ultralight fiber‑bundle Multiscopes (Chromatone) for multi-region optical functional neuroimaging. The acquisition strengthens Bruker's preclinical neuroscience imaging capabilities and complements its existing Ultima multiphoton solutions and recently acquired Inscopix products; financial terms were not disclosed.